Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Anika Therapeutics (ANIK) over the last 15 years, with Q3 2025 value amounting to $13000.0.

  • Anika Therapeutics' Gains from Investment Securities fell 9941.53% to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 13595.93%. This contributed to the annual value of $2.1 million for FY2024, which is 1524.28% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Gains from Investment Securities is $13000.0, which was down 9941.53% from $1.8 million recorded in Q2 2025.
  • Anika Therapeutics' Gains from Investment Securities' 5-year high stood at $2.3 million during Q1 2024, with a 5-year trough of -$13.6 million in Q2 2021.
  • Over the past 5 years, Anika Therapeutics' median Gains from Investment Securities value was $1.5 million (recorded in 2022), while the average stood at -$205182.3.
  • Within the past 5 years, the most significant YoY rise in Anika Therapeutics' Gains from Investment Securities was 13203.1% (2022), while the steepest drop was 139151.52% (2022).
  • Anika Therapeutics' Gains from Investment Securities (Quarter) stood at $825000.0 in 2021, then tumbled by 1391.52% to -$10.7 million in 2022, then surged by 110.14% to $1.1 million in 2023, then surged by 36.11% to $1.5 million in 2024, then tumbled by 99.12% to $13000.0 in 2025.
  • Its Gains from Investment Securities stands at $13000.0 for Q3 2025, versus $1.8 million for Q2 2025 and $1.5 million for Q1 2025.